FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registrant ...

Morsa Images/DigitalVision via Getty Images Over the last twelve months, investors applauded as the S&P 500 climbed over 21%. Unfortunately, investors in AstraZeneca (NASDAQ:AZN) don’t have much to clap about. Shares in that company are down nearly 8% over the trailing twelve months. The poor results are in part due to slowing sales of AZN’s Covid-19 vaccine. However, investors looking past that transitory headwind will find there is much to like about the company’s prospects. AZN has a strong pipeline, ...

AstraZeneca (AZN) will report first-quarter 2024 results on Apr 25, before market open. In the last reported quarter, the company missed earnings expectations by 1.35%.Factors to NoteSales of AstraZeneca’s key medicines, mainly cancer drugs — Lynparza, Tagrisso and Imfinzi — and diabetes medicine Farxiga, are expected to have driven the company’s top line in the first quarter, backed by strong demand trends. Price reductions of some drugs in emerging markets hurt product sales in the fourth quarter, a trend ...

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its ...

The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy’s resilience. The well established pharmaceutical industry continues to assert its economic dominance through resolute financials. In 2022, pharma stocks brought in $510.5 billion, with forecasts for the sector to reach $863.6 billion in revenue by 2030. Between 2023 and 2030, the industry is expected ...

AstraZeneca (AZN) announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab), for use in children. The regulatory body has now approved Fasenra as an add-on maintenance treatment for severe asthma in patients aged six to 11 years with an eosinophilic phenotype.Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA) in patients aged 12 and older.The latest approval for Fasenra was based on data from the open-label phase III TATE study, as ...

Stock Performance - Astrazeneca's stock ended at $69 45, marking a +1 97% increase from the previous day's close [1] - The stock outperformed the S&P 500, which gained 0 74%, while the Dow dropped 0 01% and the Nasdaq increased by 1 68% [1] - Over the past month, Astrazeneca's shares gained 0 78%, while the Medical sector lost 4 72% and the S&P 500 gained 0 8% [1] Earnings and Revenue Expectations - Astrazeneca is expected to report Q1 2024 EPS of $0 95, down 1 04% from the prior-year quarter [1] - Revenue for the quarter is expected to be $12 billion, a 10 27% increase compared to the year-ago quarter [1] - For the entire fiscal year, consensus estimates project earnings of $4 02 per share and revenue of $51 01 billion, representing year-over-year changes of +10 74% and +11 34%, respectively [2] Analyst Estimates and Valuation - Recent changes to analyst estimates reflect optimism about Astrazeneca's business and profitability [2] - The Zacks Consensus EPS estimate has moved 0 08% lower over the past month, and Astrazeneca currently holds a Zacks Rank of 3 (Hold) [3] - Astrazeneca is trading at a Forward P/E ratio of 16 95, a premium compared to its industry's average of 14 1 [3] - The company's PEG ratio is 1 25, lower than the industry average of 1 71 [3] Industry Overview - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 223, placing it in the bottom 12% of all industries [4] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks within the groups [4]

AstraZeneca (AZN) and partner Daiichi Sankyo announced that the FDA has granted accelerated approval to their drug Enhertu for treating unresectable or metastatic HER2-positive solid tumors in heavily pretreated patients.The approval was based on data from the three phase II studies, including the DESTINY-PanTumor02 study on Enhertu, which showed clinically meaningful responses across a broad range of tumors. The accelerated approval was based on positive objective response rate (ORR) and duration of respon ...

AstraZeneca (AZN) announced positive data from the phase III ADRIATIC study, which evaluated its blockbuster cancer drug, Imfinzi (durvalumab), for treating patients with limited-stage small cell lung cancer (LS-SCLC), an aggressive form of lung cancer.The dual primary endpoints of this global phase III study are overall survival (OS) and progression-free survival (PFS).Data from the study showed that treatment with Imfinzi led to statistically significant and clinically meaningful improvement in the OS and ...

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! Drugmakers spent big on advertisements for weight loss and diabetes treatments last year as they wrestled for dominance in the booming market for those drugs. Companies spent more than $1 billion on ads for weight loss and diabetes medicines in 2023, up 51% from the prior year, according to new data fr ...